A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy

Anti-CD20 treatment represents a therapeutic benefit for patients with B-cell lymphomas, although more efficient therapies are needed for refractory or relapsing patients. Among them, the combination of anti-CD20 and IL-2 that induces T cell response has been hampered by the expansion of FoxP3(+) Tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Casadesús, Ana Victoria, Deligne, Claire, Diallo, Béré Kadjdiatou, Sosa, Katya, Josseaume, Nathalie, Mesa, Circe, León, Kalet, Hernández, Tays, Teillaud, Jean-Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458652/
https://www.ncbi.nlm.nih.gov/pubmed/32923126
http://dx.doi.org/10.1080/2162402X.2020.1770565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458652/
https://www.ncbi.nlm.nih.gov/pubmed/32923126
http://dx.doi.org/10.1080/2162402X.2020.1770565

Ejemplares similares